Jiangxi Fushine Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.04%

Jiangxi Fushine Pharmaceutical Co Ltd (300497) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Jiangxi Fushine Pharmaceutical Co Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥1.98 Million
≈ $289.44K USD Cash + Short-term Investments

Total Assets

CN¥4.44 Billion
≈ $649.40 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Jiangxi Fushine Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Jiangxi Fushine Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300497 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.98 Million 0.04%
Total Liquid Assets CN¥1.98 Million 0.04%

Asset Resilience Insights

  • Limited Liquidity: Jiangxi Fushine Pharmaceutical Co Ltd maintains only 0.04% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangxi Fushine Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangxi Fushine Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Jiangxi Fushine Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.05% CN¥2.19 Million
≈ $319.73K
CN¥4.54 Billion
≈ $663.89 Million
+0.00pp
2023-12-31 0.05% CN¥2.19 Million
≈ $319.73K
CN¥4.82 Billion
≈ $705.18 Million
-0.94pp
2022-12-31 0.98% CN¥49.74 Million
≈ $7.28 Million
CN¥5.06 Billion
≈ $740.41 Million
-2.24pp
2021-12-31 3.22% CN¥150.76 Million
≈ $22.06 Million
CN¥4.68 Billion
≈ $684.61 Million
+0.59pp
2020-12-31 2.64% CN¥106.68 Million
≈ $15.61 Million
CN¥4.05 Billion
≈ $592.01 Million
+2.97pp
2019-12-31 -0.33% CN¥-8.69 Million
≈ $-1.27 Million
CN¥2.60 Billion
≈ $379.85 Million
-0.17pp
2018-12-31 -0.17% CN¥-3.72 Million
≈ $-544.44K
CN¥2.20 Billion
≈ $321.41 Million
-0.18pp
2017-12-31 0.01% CN¥114.11K
≈ $16.70K
CN¥1.79 Billion
≈ $261.85 Million
-12.15pp
2016-12-31 12.16% CN¥170.00 Million
≈ $24.88 Million
CN¥1.40 Billion
≈ $204.63 Million
+12.15pp
2013-12-31 0.00% CN¥13.23K
≈ $1.94K
CN¥541.31 Million
≈ $79.21 Million
-0.02pp
2011-12-31 0.03% CN¥96.12K
≈ $14.07K
CN¥352.57 Million
≈ $51.59 Million
--
pp = percentage points

About Jiangxi Fushine Pharmaceutical Co Ltd

SHE:300497 China Biotechnology
Market Cap
$1.52 Billion
CN¥10.41 Billion CNY
Market Cap Rank
#7322 Global
#1741 in China
Share Price
CN¥19.32
Change (1 day)
-2.57%
52-Week Range
CN¥8.37 - CN¥21.15
All Time High
CN¥24.76
About

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more